5-Phenethyl-1-propyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one | 1027234-20-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 5-Phenethyl-1-propyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one
• 英文别名: 5-(2-Phenylethyl)-1-propyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one；5-(2-phenylethyl)-1-propyl-3H-1,4-benzodiazepin-2-one
• CAS: 1027234-20-3
• 化学式: C₂₀H₂₂N₂O
• 分子量: 306.407
• InChiKey: CAJMZURXUXYJIB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-Phenethyl-1-propyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 在 双(三甲基硅烷基)氨基钾 、 三苯基膦 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 3-amino-5-(2-phenylethyl)-1-propyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
  参考文献：
  名称：

  Benzodiazepines as Potent and Selective Bradykinin B₁ Antagonists

  摘要：

  Antagonism of the bradykinin B-1 receptor was demonstrated to be a potential treatment for chronic pain and inflammation. Novel benzodiazepines were designed that display subnanomolar affinity for the bradykinin B, receptor (K-i = 0.59 nM) and high selectivity against the bradykinin B-2 receptor (K-i > 10 muM). In vivo efficacy, comparable to morphine, was demonstrated for lead compounds in a rodent hyperalgesia model.

  DOI：

  10.1021/jm034020y
• 作为产物：
  描述：

  1-碘代丙烷 、 5-phenethyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 5-Phenethyl-1-propyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one
  参考文献：
  名称：

  Benzodiazepines as Potent and Selective Bradykinin B₁ Antagonists

  摘要：

  Antagonism of the bradykinin B-1 receptor was demonstrated to be a potential treatment for chronic pain and inflammation. Novel benzodiazepines were designed that display subnanomolar affinity for the bradykinin B, receptor (K-i = 0.59 nM) and high selectivity against the bradykinin B-2 receptor (K-i > 10 muM). In vivo efficacy, comparable to morphine, was demonstrated for lead compounds in a rodent hyperalgesia model.

  DOI：

  10.1021/jm034020y

文献信息

• Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
  申请人：Tung S. Jay

  公开号：US20050020659A1

  公开（公告）日：2005-01-27

  Disclosed are compounds that are bradykinin B 1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B 1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

  本发明公开了一种布雷肯肽B1受体拮抗剂化合物，可用于治疗哺乳动物中由布雷肯肽B1受体介导的疾病或缓解与疾病状况相关的不良症状。其中某些化合物表现出增强的效力，并且预计也会表现出增强的作用持续时间。
• 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
  申请人：Tung S. Jay

  公开号：US20060281733A1

  公开（公告）日：2006-12-14

  Disclosed are compounds of formula I and II that are bradykinin B 1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B 1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

  本发明公开了式I和式II的化合物，它们是缓激肽B1受体拮抗剂，可用于治疗哺乳动物中由缓激肽B1受体介导的疾病，或缓解与疾病条件相关的不良症状。其中某些化合物表现出增强的效力，预计也会表现出增强的持续时间。
• US7417152B2
  申请人：——

  公开号：US7417152B2

  公开（公告）日：2008-08-26
• US7432379B2
  申请人：——

  公开号：US7432379B2

  公开（公告）日：2008-10-07
• Benzodiazepines as Potent and Selective Bradykinin B₁ Antagonists
  作者：Michael R. Wood、June J. Kim、Wei Han、Bruce D. Dorsey、Carl F. Homnick、Robert M. DiPardo、Scott D. Kuduk、Tanya MacNeil、Kathy L. Murphy、Edward V. Lis、Richard W. Ransom、Gary L. Stump、Joseph J. Lynch、Stacey S. O'Malley、Patricia J. Miller、Tsing-Bau Chen、Charles M. Harrell、Raymond S. L. Chang、Punam Sandhu、Joan D. Ellis、Peter J. Bondiskey、Douglas J. Pettibone、Roger M. Freidinger、Mark G. Bock

  DOI：10.1021/jm034020y

  日期：2003.5.1

  Antagonism of the bradykinin B-1 receptor was demonstrated to be a potential treatment for chronic pain and inflammation. Novel benzodiazepines were designed that display subnanomolar affinity for the bradykinin B, receptor (K-i = 0.59 nM) and high selectivity against the bradykinin B-2 receptor (K-i > 10 muM). In vivo efficacy, comparable to morphine, was demonstrated for lead compounds in a rodent hyperalgesia model.